STAAR Surgical Eyes 2026 Profit After Volatile Year

Staar Surgical Company ((STAA)) has held its Q4 earnings call. Read on for the main highlights of the call.

STAAR Surgical’s latest earnings call struck a tone of cautious optimism, as management balanced solid operational improvement with frank acknowledgment of recent missteps. The company showcased strong Q4 sales growth, margin expansion and near-breakeven adjusted EBITDA, yet emphasized that China channel issues, EMEA disruption and merger fallout will weigh on the near term while 2026 is framed as the real inflection year.

Q4 Revenue Accelerates on China and Americas Strength

STAAR reported Q4 FY2025 net sales of $57.8 million, up about 18% from $49.0 million a year earlier, underscoring a meaningful rebound after a turbulent year. Management highlighted that the growth was driven largely by a sharp recovery in China and improved performance in the Americas, even as other regions lagged.

China’s Quarterly Sales Rebound Masks Channel Noise

China net sales surged to $17.5 million in Q4 from just $7.8 million a year ago, a roughly 124% year-over-year increase that signals in-market demand is recovering. Executives cautioned that this improvement came despite ongoing channel inventory dynamics, which continue to inject volatility into reported revenue.

Adjusted EBITDA Nearly Breaks Even as Profit Focus Intensifies

Adjusted EBITDA improved dramatically, narrowing to a loss of $0.2 million in Q4 from a loss of $20.8 million in the prior-year quarter, reflecting better gross profit and leaner operating expenses. Management reiterated a clear target of achieving full-year profitability in FY2026, positioning current cost actions and operational upgrades as the bridge to that goal.

Gross Margins Jump on Cost Actions and Swiss Ramp

Gross margin expanded to 75.7% of net sales in Q4, up from 64.7% a year earlier, an improvement of roughly 11 percentage points that stood out on the call. The company credited the gain to timing of cost recognition, internal cost reductions and the ramp-up of Swiss manufacturing, although some of these benefits are expected to normalize.

Operating Expenses Tightened Despite Merger Turbulence

Excluding merger and restructuring charges, Q4 operating expenses were $54.7 million, down 8.2% from the prior-year quarter as management pushed hard on cost control. STAAR also brought its annualized adjusted opex run rate below its second-half $225 million target, reinforcing the narrative of disciplined spending alongside growth investments.

Debt-Free Balance Sheet Underpins Strategic Flexibility

The balance sheet remains a bright spot, with cash, cash equivalents and marketable securities totaling about $187.5 million at quarter end and no debt. Importantly, the company managed to maintain this cash cushion even while absorbing restructuring and merger-related expenses, giving it flexibility to fund manufacturing and commercial initiatives.

Swiss Manufacturing Boosts Resilience and Future Margins

STAAR accelerated commercial production at its Nidau, Switzerland facility to reduce exposure to U.S.-China tariffs and secure supply for EVO+ in China. Management framed Swiss manufacturing as a key lever for operational flexibility and longer-term margin benefits, even as higher near-term costs from this inventory will pressure 2026 gross margins.

Product Launches and Platforms Fuel Commercial Momentum

The company launched EVO+ in China, its first new lens in the market in more than a decade, and is expanding the Lioli injector across EMEA to support surgeon adoption. At the same time, STAAR is rolling out its Stella sizing and ordering platform and finalizing Oracle ERP deployment to enhance commercial readiness, data visibility and overall efficiency.

Americas and U.S. Demand Show Solid Underlying Strength

The Americas region delivered 18% growth in Q4, with management spotlighting continued momentum in the U.S. as a core earnings driver. The expanded U.S. EVO indication for patients aged 21 to 60 adds roughly 8 million new potential candidates, which the company believes will support sustained double-digit growth in the domestic market.

China Channel Inventory Rebalancing Distorts Reported Sales

Management detailed a significant inventory rebalancing in China following a large $27.5 million shipment in December 2024 that left distributors overstocked. STAAR deliberately paused shipments and allowed inventories to normalize toward contractual levels, a move that dampened near-term net sales recognition but is intended to prevent future channel build-ups.

Distributor Returns in China Weigh on Q4 Top Line

During Q4 some China subdistributors and customers returned inventory to main distributors, a development that reduced STAAR’s recognized net sales below internal expectations. Management stressed that these returns masked an underlying recovery in in-market demand and procedures, but they also underscored past gaps in channel oversight.

Ex-China and EMEA Markets Struggle Amid Transition

Excluding China, Q4 net sales slipped 2% year over year, highlighting that not all regions are firing. EMEA was particularly weak, down 20% in the quarter as the business navigated a distributor transition in the Middle East and merger-related distributor dynamics, which together disrupted ordering patterns.

Merger and Restructuring Costs Cloud Operating Picture

Operating expenses in Q4 included $11.2 million tied to the terminated Alcon merger and $0.7 million of restructuring charges, which materially weighed on reported results. Management framed these as largely non-recurring items, yet the drag on earnings underscored how strategic turbulence can complicate near-term performance.

Higher Inventory Provisions Create Near-Term Margin Headwinds

The company disclosed higher inventory provisions in Q4 and guided to slightly lower gross margins in FY2026 as higher-cost Swiss-manufactured inventory is sold through. Additional reserves for expiring product will also pressure profitability in the near term, even as these clean-up actions are meant to de-risk the balance sheet.

China Macro Backdrop Remains a Wild Card

While STAAR is cautiously optimistic about China’s recovery, management warned that macro factors like housing market weakness and uneven consumer spending could still affect procedure volumes. This uncertainty makes the pace and durability of Chinese demand recovery one of the key swing factors for investors watching 2026.

Improving but Imperfect Visibility into Downstream Inventory

Executives acknowledged that for much of the past year the company lacked full visibility into downstream inventory and procedures, contributing to the earlier channel build-up in China. They emphasized that data processes have improved materially, but that inventory tracking and demand sensing remain active workstreams to prevent future dislocations.

Direction-Only Outlook Targets 2026 Profitability

STAAR declined to issue formal FY2026 financial guidance, instead offering directional commentary that leaves investors with more modeling uncertainty. Management is targeting full-year profitability next year, expects gross margin to run slightly below 2025 levels due to Swiss inventory and higher reserves, plans to keep operating expenses aligned with the $225 million run-rate, and forecasts modest near-term cash usage before resuming cash generation in the second half and exiting 2026 with a higher cash balance.

STAAR’s earnings call painted a picture of a company emerging from a year of channel and merger disruption with improving operations but meaningful near-term noise. For investors, the key takeaway is that Q4 showcased real progress in growth, margins and cost control, yet the true test will be whether management can navigate China volatility, EMEA recovery and inventory clean-up to deliver on its 2026 profitability ambitions.